PT-141 (Bremelanotide) Global Regulatory Status
HealthRX.com
Bremelanotide is FDA-approved as Vyleesi, not compounded PT-141
Key numbers
- 1.75 mgDose of the prescription-only Vyleesi subcutaneous autoinjectorSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 24 weeksTreatment duration of the phase 3 trials of bremelanotide or placebo in premenopausal womenSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 8 doses per monthMaximum monthly Vyleesi doses the label does not recommend exceedingSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Patents and generic approvals for bremelanotide
The FDA Orange Book lists 0 approved generic applications for bremelanotide across 1 listed product. 4 listed patents have not yet expired, the last on 2041-04-29.
| Measure | Value |
|---|---|
| Brand-name applications (NDA) | 1 |
| Approved generic applications (ANDA) | 0 |
| Listed patents not yet expired | 4 |
| Latest listed patent expiry | 2041-04-29 |
| Earliest approval date on file | 2019-06-21 |
| Products not marked discontinued | 1 of 1 |
How this was calculated
Selected Orange Book products whose only active ingredient is this substance, then counted applications by type and the distinct patents and exclusivities listed against them. Expired patents are left out.
All single-ingredient bremelanotide products in the Orange Book, every brand and strength, files dated 2026-10-09
An approved generic or an expired patent does not show that a generic is on sale. Launch timing also depends on litigation, settlements and supply. Biologics and compounded products are not in the Orange Book.
From the public record
FDA approval history for bremelanotide
The earliest FDA approval on file for a bremelanotide product is 2019-06-21. Drugs@FDA lists 1 application for it and 2 approved supplements, the most recent on 2026-10-22.
| Measure | Value | Note |
|---|---|---|
| Earliest FDA approval on file | 2019-06-21 | |
| Applications with an approval on file | 1 | |
| New drug applications (NDA) | 1 | |
| Generic applications (ANDA) | 0 | |
| Approved supplements | 2 | label, manufacturing and efficacy changes |
| Most recent supplement approval | 2026-10-22 | |
| Sponsoring companies | 1 |
How this was calculated
Selected applications with a product whose only active ingredient is this substance, then counted approved original and supplemental submissions. The earliest approved original submission is the first approval.
Applications with a single-ingredient bremelanotide product in Drugs@FDA, all sponsors and strengths
Older approvals can be missing dates, and tentative approvals are not counted. An approved application does not mean the product is currently marketed.
From the public record
FDA label facts for bremelanotide
The FDA label read for bremelanotide (Vyleesi, application NDA210557) was last revised on 2026-11-05. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.
| Measure | Value | Note |
|---|---|---|
| Label revision date | 2026-11-05 | |
| Label read | Vyleesi | NDA210557, brand-name application |
| Boxed warning | No | |
| Pregnancy section | Present | |
| Lactation section | Present | |
| Pediatric use section | Present | |
| Geriatric use section | Present |
How this was calculated
Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.
One label: the newest prescription label for single-ingredient bremelanotide from an original manufacturer
Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.
At a glance
- U.S. approval / Vyleesi, NDA 210557, June 21, 2019 [1][2]
- Current NDA holder / Cosette Pharmaceuticals [2]
- Approved population / Premenopausal women with acquired, generalized HSDD [1]
- Not approved for / Postmenopausal women, men, or sexual performance enhancement [1]
- Boxed warning / None in the Vyleesi label [1]
- Compounded PT-141 / Not Vyleesi; not FDA-approved [3]
- WADA 2026 Prohibited List / Not named [8]
What did the FDA approve?
Bremelanotide is FDA-approved as Vyleesi under NDA 210557, original approval June 21, 2019; Cosette Pharmaceuticals is the current holder, AMAG the original one [1][4][2]. It is prescription only, a 1.75 mg subcutaneous autoinjector [1].
The approved use is premenopausal women with acquired, generalized HSDD: low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says Vyleesi is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1]. The label carries no boxed warning, and the 2019 approval letter includes no REMS [1][4].
What trial data supported approval?
Two identical phase 3 trials randomized 1,267 premenopausal women with HSDD to bremelanotide 1.75 mg or placebo for 24 weeks; 1,247 were in the safety population and 1,202 in the modified intent-to-treat efficacy population [5][1]. Mean change from baseline on the FSFI-desire domain was 0.5 with Vyleesi versus 0.2 with placebo in Study 1, and 0.6 versus 0.2 in Study 2 [1]. The trials did not show a significant difference in the number of satisfying sexual events [5].
What changed in the U.S. label in 2026?
On October 22, 2026, FDA approved a labeling supplement (S-005) that updates Section 8 (Use in Specific Populations) and the patient information [2][10]. The DailyMed label used for this page has an effective date of November 13, 2025, and does not yet show that new text.
What does the U.S. label say about use?
The approved Vyleesi regimen is 1.75 mg injected under the skin of the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity. The label limits use to one dose in 24 hours and does not recommend more than 8 doses per month [1]. The label lists uncontrolled hypertension and known cardiovascular disease as contraindications [1].
What about compounded PT-141?
Compounded PT-141 is not Vyleesi, the FDA-approved bremelanotide product. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing [3]. Bremelanotide is not listed among FDA's bulk substances that may present significant safety risks when compounded, content dated April 22, 2026 [7]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [9].
Questions worth asking
Is bremelanotide on the WADA Prohibited List?
Bremelanotide is not named on WADA's 2026 Prohibited List [8]. Because it is FDA-approved, WADA's S0 class for substances with no approval from any governmental health authority does not cover it by definition [8].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is PT-141 the same as Vyleesi?
What is Vyleesi approved to treat?
What dose does the Vyleesi label specify?
Is bremelanotide on the WADA Prohibited List?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is PT-141 FDA approved?
Yes. Bremelanotide is FDA-approved as Vyleesi under NDA 210557 for premenopausal women with acquired, generalized HSDD. Compounded PT-141 is not Vyleesi and is not an FDA-approved drug. Vyleesi is prescription only and comes as a 1.75 mg subcutaneous autoinjector.
Where can I buy bremelanotide PT-141?
No sellers or sources are named. Vyleesi is prescription only, given as a 1.75 mg subcutaneous autoinjector. Compounded PT-141 is not Vyleesi and is not FDA-approved, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
References
Show all 10 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Drugs@FDA: FDA-Approved Drugs.
- Compounding and the FDA: Questions and Answers | FDA.
- U.S. Food and Drug Administration.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- Medicines | European Medicines Agency (EMA).
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- U.S. Department of Health and Human Services. HHS 503A peptide enforcement discretion policy, Appendix B. HHS peptide enforcement discretion policy appendix B
- U.S. Food and Drug Administration. NDA 210557 supplement 5 approval letter, October 22, 2026.